Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...
mRNA Vaccines dominated the market in 2024, accounting for over US$ 36 billion in revenues. Pfizer, Moderna, and BioNTech ...